Browsing byAuthorRoberts, MJ

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)
2016-09Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.Roberts, MJ; Yaxley, JW; Coughlin, GD; Gianduzzo, TRJ; Esler, RC; Dunglison, NT; Chambers, SK; Medcraft, RJ; Chow, CWK; Schirra, HJ; Richards, RS; Kienzle, N; Lu, M; Brereton, I; Samaratunga, H; Perry-Keene, J; Payton, D; Oyama, C; Doi, SA; Lavin, MF; Gardiner, RA
2023-12-06Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.Buteau, JP; Moon, D; Fahey, MT; Roberts, MJ; Thompson, J; Murphy, DG; Papa, N; Mitchell, C; De Abreu Lourenco, R; Dhillon, HM; Kasivisvanathan, V; Francis, RJ; Stricker, P; Agrawal, S; O'Brien, J; McVey, A; Sharma, G; Levy, S; Ayati, N; Nguyen, A; Lee, S-F; Pattison, DA; Sivaratnam, D; Frydenberg, M; Du, Y; Titus, J; Lee, S-T; Ischia, J; Jack, G; Hofman, MS; Emmett, L
2023-05-18Guidelines for genetic testing in prostate cancer: a scoping review.Tuffaha, H; Edmunds, K; Fairbairn, D; Roberts, MJ; Chambers, S; Smith, DP; Horvath, L; Arora, S; Scuffham, P
2023-08-21The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.Roberts, MJ; Conduit, C; Davis, ID; Effeney, RM; Williams, S; Martin, JM; Hofman, MS; Hruby, G; Eapen, R; Gianacas, C; Papa, N; Lourenço, RDA; Dhillon, HM; Allen, R; Fontela, A; Kaur, B; Emmett, L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP),